Completed PHASE1 INTERVENTIONAL 1-arm NCT00431054

Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer

Pharmacodynamic Trial: Molecular Marker & Imaging Studies as Primary Endpoints to Determine Optimal Biological Dosage of Perifosine, Orally Avail AKT PH Domain Inhibitor Combined w/ Docetaxel in Patients w/Relapsed Epithelial Ovarian Cancer

Sponsor: Keryx Biopharmaceuticals

Conditions Ovarian Cancer

Interventions Docetaxel Perifosine

Updated 5 times since 2017 Last updated: Feb 17, 2016 Started: Feb 28, 2007 Primary completion: May 31, 2012 Completion: May 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00431054, this PHASE1 trial focuses on Ovarian Cancer and remains completed. Sponsored by Keryx Biopharmaceuticals, it has been updated 5 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Keryx Biopharmaceuticals
M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States